Search

Your search keyword '"Som, M"' showing total 473 results
Start Over Author "Som, M"
473 results on '"Som, M"'

4. Gravitational field of an infinitely long supermassive cosmic string

Author

Som, M. M. and Souza, Marcelo de Oliveira

Subjects
General Relativity and Quantum Cosmology
Abstract

We obtain an exact solution of the coupled Einstein-scalar-gauge field equations for a local infinitely long supermassive cosmic string. The solution correponds to that of Hiscock-Gott . The string appears to be due to the freezing of the scalar field at the null value giving rise to a constant linear energy density., Comment: Latex, 8 pages

Published
1994

6. Exploration par imagerie par résonance magnétique fonctionnelle (IRMf) des processus neurocognitifs impliqués dans les addictions alimentaires chez des patientes souffrant d’obésité sévère

Author

Guittière, M.O., primary, Coquery, N., additional, Som, M., additional, Serrand, Y., additional, Bannier, E., additional, Lainé, F., additional, Constant, A., additional, Moirand, R., additional, Val-Laillet, D., additional, and Thibault, R., additional

Published
2023
Full Text
View/download PDF

9. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Author

Marconi, V, Ramanan, A, de Bono, S, Kartman, C, Krishnan, V, Liao, R, Piruzeli, M, Goldman, J, Alatorre-Alexander, J, de Cassia Pellegrini, R, Estrada, V, Som, M, Cardoso, A, Chakladar, S, Crowe, B, Reis, P, Zhang, X, Adams, D, Ely, E, Ahn, M, Akasbi, M, Altclas, J, Ariel, F, Ariza, H, Atkar, C, Bertetti, A, Bhattacharya, M, Briones, M, Budhraja, A, Burza, A, Camacho Ortiz, A, Caricchio, R, Casas, M, Cevoli Recio, V, Choi, W, Cohen, E, Comulada-Rivera, A, Cook, P, Cornejo Juarez, D, Daniel, C, Degrecci Relvas, L, Dominguez Cherit, J, Ellerin, T, Enikeev, D, Erico Tanni Minamoto, S, Fiss, E, Furuichi, M, Giovanni Luz, K, Gonzalez, O, Gordeev, I, Gruenewald, T, Hamamoto Sato, V, Heo, E, Heo, J, Hermida, M, Hirai, Y, Hutchinson, D, Iastrebner, C, Ioachimescu, O, Jain, M, Juliani Souza Lima, M, Khan, A, Kremer, A, Lawrie, T, Macelwee, M, Madhani-Lovely, F, Malhotra, V, Martinez Resendez, M, Mckinnell, J, Milligan, P, Minelli, C, Moran Rodriguez, M, Parody, M, Paulin, P, Pellegrini, R, Pemu, P, Procopio Carvalho, A, Puoti, M, Purow, J, Ramesh, M, Rea Neto, A, Robinson, P, Rodrigues, C, Rojas Velasco, G, Saraiva, J, Scheinberg, M, Schreiber, S, Scublinsky, D, Sevciovic Grumach, A, Shawa, I, Simon Campos, J, Sofat, N, Spinner, C, Sprinz, E, Stienecker, R, Suarez, J, Tachikawa, N, Tahir, H, Tiffany, B, Vishnevsky, A, Westheimer Cavalcante, A, Zirpe, K, Marconi V. C., Ramanan A. V., de Bono S., Kartman C. E., Krishnan V., Liao R., Piruzeli M. L. B., Goldman J. D., Alatorre-Alexander J., de Cassia Pellegrini R., Estrada V., Som M., Cardoso A., Chakladar S., Crowe B., Reis P., Zhang X., Adams D. H., Ely E. W., Ahn M. -Y., Akasbi M., Altclas J. D., Ariel F., Ariza H. A., Atkar C., Bertetti A., Bhattacharya M., Briones M. L., Budhraja A., Burza A., Camacho Ortiz A., Caricchio R., Casas M., Cevoli Recio V., Choi W. S., Cohen E., Comulada-Rivera A., Cook P., Cornejo Juarez D. P., Daniel C., Degrecci Relvas L. F., Dominguez Cherit J. G., Ellerin T., Enikeev D., Erico Tanni Minamoto S., Fiss E., Furuichi M., Giovanni Luz K., Gonzalez O., Gordeev I., Gruenewald T., Hamamoto Sato V. A., Heo E. Y., Heo J. Y., Hermida M., Hirai Y., Hutchinson D., Iastrebner C., Ioachimescu O., Jain M., Juliani Souza Lima M. P., Khan A., Kremer A. E., Lawrie T., MacElwee M., Madhani-Lovely F., Malhotra V., Martinez Resendez M. F., McKinnell J., Milligan P., Minelli C., Moran Rodriguez M. A., Parody M. L., Paulin P., Pellegrini R. D. C., Pemu P., Procopio Carvalho A. C., Puoti M., Purow J., Ramesh M., Rea Neto A., Robinson P., Rodrigues C., Rojas Velasco G., Saraiva J. F. K., Scheinberg M., Schreiber S., Scublinsky D., Sevciovic Grumach A., Shawa I., Simon Campos J., Sofat N., Spinner C. D., Sprinz E., Stienecker R., Suarez J., Tachikawa N., Tahir H., Tiffany B., Vishnevsky A., Westheimer Cavalcante A., Zirpe K., Marconi, V, Ramanan, A, de Bono, S, Kartman, C, Krishnan, V, Liao, R, Piruzeli, M, Goldman, J, Alatorre-Alexander, J, de Cassia Pellegrini, R, Estrada, V, Som, M, Cardoso, A, Chakladar, S, Crowe, B, Reis, P, Zhang, X, Adams, D, Ely, E, Ahn, M, Akasbi, M, Altclas, J, Ariel, F, Ariza, H, Atkar, C, Bertetti, A, Bhattacharya, M, Briones, M, Budhraja, A, Burza, A, Camacho Ortiz, A, Caricchio, R, Casas, M, Cevoli Recio, V, Choi, W, Cohen, E, Comulada-Rivera, A, Cook, P, Cornejo Juarez, D, Daniel, C, Degrecci Relvas, L, Dominguez Cherit, J, Ellerin, T, Enikeev, D, Erico Tanni Minamoto, S, Fiss, E, Furuichi, M, Giovanni Luz, K, Gonzalez, O, Gordeev, I, Gruenewald, T, Hamamoto Sato, V, Heo, E, Heo, J, Hermida, M, Hirai, Y, Hutchinson, D, Iastrebner, C, Ioachimescu, O, Jain, M, Juliani Souza Lima, M, Khan, A, Kremer, A, Lawrie, T, Macelwee, M, Madhani-Lovely, F, Malhotra, V, Martinez Resendez, M, Mckinnell, J, Milligan, P, Minelli, C, Moran Rodriguez, M, Parody, M, Paulin, P, Pellegrini, R, Pemu, P, Procopio Carvalho, A, Puoti, M, Purow, J, Ramesh, M, Rea Neto, A, Robinson, P, Rodrigues, C, Rojas Velasco, G, Saraiva, J, Scheinberg, M, Schreiber, S, Scublinsky, D, Sevciovic Grumach, A, Shawa, I, Simon Campos, J, Sofat, N, Spinner, C, Sprinz, E, Stienecker, R, Suarez, J, Tachikawa, N, Tahir, H, Tiffany, B, Vishnevsky, A, Westheimer Cavalcante, A, Zirpe, K, Marconi V. C., Ramanan A. V., de Bono S., Kartman C. E., Krishnan V., Liao R., Piruzeli M. L. B., Goldman J. D., Alatorre-Alexander J., de Cassia Pellegrini R., Estrada V., Som M., Cardoso A., Chakladar S., Crowe B., Reis P., Zhang X., Adams D. H., Ely E. W., Ahn M. -Y., Akasbi M., Altclas J. D., Ariel F., Ariza H. A., Atkar C., Bertetti A., Bhattacharya M., Briones M. L., Budhraja A., Burza A., Camacho Ortiz A., Caricchio R., Casas M., Cevoli Recio V., Choi W. S., Cohen E., Comulada-Rivera A., Cook P., Cornejo Juarez D. P., Daniel C., Degrecci Relvas L. F., Dominguez Cherit J. G., Ellerin T., Enikeev D., Erico Tanni Minamoto S., Fiss E., Furuichi M., Giovanni Luz K., Gonzalez O., Gordeev I., Gruenewald T., Hamamoto Sato V. A., Heo E. Y., Heo J. Y., Hermida M., Hirai Y., Hutchinson D., Iastrebner C., Ioachimescu O., Jain M., Juliani Souza Lima M. P., Khan A., Kremer A. E., Lawrie T., MacElwee M., Madhani-Lovely F., Malhotra V., Martinez Resendez M. F., McKinnell J., Milligan P., Minelli C., Moran Rodriguez M. A., Parody M. L., Paulin P., Pellegrini R. D. C., Pemu P., Procopio Carvalho A. C., Puoti M., Purow J., Ramesh M., Rea Neto A., Robinson P., Rodrigues C., Rojas Velasco G., Saraiva J. F. K., Scheinberg M., Schreiber S., Scublinsky D., Sevciovic Grumach A., Shawa I., Simon Campos J., Sofat N., Spinner C. D., Sprinz E., Stienecker R., Suarez J., Tachikawa N., Tahir H., Tiffany B., Vishnevsky A., Westheimer Cavalcante A., and Zirpe K.

Abstract

Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. Methods: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027. Findings: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of −2·7 percentage points (

Published
2021

16. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Author

Marconi V, Ramanan A, de Bono S, Kartman C, Krishnan V, Liao R, Piruzeli M, Goldman J, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams D, Ely E, and COV-BARRIER Study Group

Abstract

BACKGROUND: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. METHODS: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027. FINDINGS: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of -2·7 percentage points (95% CI -7·3 to 1·9). The 28-day all-cause mortality was 8% (n=62) for baricitinib and 13% (n=100) for placebo (hazard ratio [HR] 0·57 [95% CI 0·41-0·78]; nominal p=0·0018), a 38·2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. The 60-day all-cause mortality was 10% (n=79) for baricitinib and 15% (n=116) for placebo (HR 0·62 [95% CI 0·47-0·83]; p=0·0050). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups. INTERPRETATION: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19. FUNDING: Eli Lilly and Company. TRANSLATIONS: For the French, Japanese, Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results